Frankincense and myrrh and their bioactive compounds ameliorate the multiple myeloma through regulation of metabolome profiling and JAK/STAT signaling pathway based on U266 cells

Gao, Rumeng; Miao, Xiaodong; Sun, Chengjing; Su, Shulan; Zhu, Yue; Qian, Dawei; Ouyang, Zhen; Duan, Jinao

doi:10.1186/s12906-020-2874-0

BMC Complementary Medicine and Therapies

Table 4 Potential metabolites selected and identified between treated groups and control group

From: Frankincense and myrrh and their bioactive compounds ameliorate the multiple myeloma through regulation of metabolome profiling and JAK/STAT signaling pathway based on U266 cells

No.	T_R/min	*m/z*	Identification	Formula	VIP	Trend	HMDB ID
Control vs. RXC
1	1.12	218.1504	Gamma-glutamyl-L-putrescine	C₉H₁₉N3O₃	3.24	↓	12,230
2	1.58	120.0872	L-Homoserine	C₄H₉NO₃	3.35	↓	00719
3	2.42	203.0942	3-Hydroxy-N6,N6,N6-trimethyl-L-lysine	C₉H₂₁N₂O₃	1.50	↓	01422
4	2.80	180.0756	Hippuric acid	C₉H₉NO₃	2.35	↓	00714
6	3.97	137.0335	Urocanic acid	C₆H₆N₂O₂	1.14	↑	00301
7	4.64	192.0603	L-Dopachrome	C₉H₇NO₄	5.65	↓	01430
8	5.25	181.0242	Galactitol	C₆H₁₄O₆	1.51	↓	00107
9	6.52	448.3382	Chenodeoxycholic acid glycine conjugate	C₂₆H₄₃NO₅	2.34	↓	00637
10	8.33	315.2742	Pregnenolone	C₂₁H₃₂O₂	1.55	↓	00253
11	10.83	524.4035	LysoPC(18:0)	C₂₆H₅₄NO₇P	3.56	↑	10,384
12	11.93	305.2663	Arachidonic acid	C₂₀H₃₂O₂	1.84	↓	01043
13	13.85	112.9931	Dihydrouracil	C₄H₆N₂O₂	2.38	↑	00076
Control vs. MYC
1	1.12	218.1504	Gamma-glutamyl-L-putrescine	C₉H₁₉N₃O₃	3.61	↓	12,230
2	1.57	120.0877	L-Homoserine	C₄H₉NO₃	2.62	↓	00719
3	2.43	188.0816	2-Keto-6-acetamidocaproate	C₈H₁₃NO₄	1.95	↓	12,150
4	2.80	180.0759	2-Methyl-3-hydroxy-5-formylpyridine-4-carboxylate	C₈H₇NO₄	2.06	↓	06954
5	3.62	355.088	5-Amino-6-(5′-phosphoribitylamino)uracil	C₉H₁₇N₄O₉P	2.18	↓	03841
6	4.65	176.0805	Indoleacetic acid	C₁₀H₉NO₂	1.61	↑	00197
7	9.38	496.3721	LysoPC(16:0)	C₂₄H₅₀NO₇P	1.96	↑	10,382
8	9.75	149.0322	trans-Cinnamic acid	C₉H₈O₂	2.58	↑	00930
Control vs. YDC
1	2.80	180.0751	2-Methyl-3-hydroxy-5-formylpyridine-4-carboxylate	C₈H₇NO₄	1.92	↓	06954
2	3.26	160.0514	Aminoadipic acid	C₆H₁₁NO₄	1.41	↓	00510
3	3.62	355.0865	5-Amino-6-(5′-phosphoribitylamino)uracil	C₉H₁₇N₄O₉P	3.71	↓	03841
4	3.96	218.2238	Gamma-glutamyl-L-putrescine	C₉H₁₉N₃O₃	2.01	↓	12,230
5	4.00	171.1582	Capric acid	C₁₀H₂₀O₂	1.82	↑	00511
6	9.72	149.0310	trans-Cinnamic acid	C₉H₈O₂	1.63	↑	00930
7	10.06	328.2811	Dihydroceramide	C₁₉H₃₉NO₃	1.63	↑	06752
Control vs. YDS
1	1.58	120.0869	L-Homoserine	C₄H₉NO₃	3.42	↓	00719
2	2.43	188.0806	2-Keto-6-acetamidocaproate	C₈H₁₃NO₄	2.87	↓	12,150
3	2.80	180.0754	2-Methyl-3-hydroxy-5-formylpyridine-4-carboxylate	C₈H₇NO₄	2.43	↓	06954
4	3.96	218.2238	Gamma-glutamyl-L-putrescine	C₉H₁₉N₃O₃	2.17	↓	12,230
5	7.47	460.2969	Galactosylsphingosine	C₂₄H₄₇NO₇	2.08	↓	00648
6	10.82	524.4034	LysoPC(18:0)	C₂₆H₅₄NO₇P	4.53	↑	10,384
7	11.21	289.2684	All-trans-13,14-dihydroretinol	C₂₀H₃₂O	4.57	↑	11,618

Back to article page

ISSN: 2662-7671

Contact us

Submission enquiries: bmccomplementarymedicineandtherapies@biomedcentral.com
General enquiries: ORSupport@springernature.com